Specific Immunotherapy for Rhinitis and Asthma with a Subcutaneous Hypoallergenic High-Dose House Dust Mite Extract: Results of a 9-Month Therapy

El-Qutob, David; Moreno, Francisco; Subtil‐Rodríguez, Alicia

doi:10.2217/imt-2015-0017

Cited by 7 publications

(6 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We also considered costs related to asthma moderate and severe exacerbations according to the probability of emergency department (ED) visits and hospitalizations, respectively, based on contracted values for Portuguese public hospitals (28). For both AIT strategies, asthma medication costs and exacerbations were reduced based on literature findings; the use of drugs was reduced by 34% and exacerbations leading to ED visits or hospitalizations due to asthma were reduced by 74% (20,30). The previous effects on asthma were included in the model for patients taking and completing three years of immunotherapy.…”

Section: F O R P U B L I C a T I O Nmentioning

confidence: 99%

Cost-effectiveness analysis of grass pollen specific immunotherapy in children with allergic rhinitis compared to the standard of care symptomatic treatment in Portugal

Farraia

Paciência

Mendes

et al. 2023

Eur Ann Allergy Clin Immunol

View full text Add to dashboard Cite

Background. Cost-effectiveness studies evaluating allergen immunotherapy (AIT) in children are scarce. We aim to compare the cost-effectiveness of subcutaneous (SCIT) and sublingual immunotherapy (SLIT) against standard-of-care (SOC) treatment in children with grass pollen allergic rhinitis.Methods. We created a Markov model to compare the three strategies over a 10-year horizon.SOC was the reference to calculate the incremental cost-effectiveness ratio (ICER). Deterministic and probabilistic sensitivity analysis were used to assess models' uncertainty.Results. We obtained an ICER of 12605€ and 6318€ for SLIT and SCIT, respectively. In sensitivity analysis, SCIT was more cost-effective than SLIT. Conclusion.AIT is cost-effective in children with grass pollen allergic rhinitis, especially for the subcutaneous route.

show abstract

Section: F O R P U B L I C a T I O Nmentioning

confidence: 99%

Cost-effectiveness analysis of grass pollen specific immunotherapy in children with allergic rhinitis compared to the standard of care symptomatic treatment in Portugal

Farraia

Paciência

Mendes

et al. 2023

Eur Ann Allergy Clin Immunol

View full text Add to dashboard Cite

show abstract

“…We were able to obtain the probability of medication-step down and discontinuation of medications in patients with moderate persistent asthma that received SCIT from a real-world study in Colombia by Sánchez et al (23). In addition, we estimated the baseline probability of an asthma exacerbation using data form a population-based study by Dennis et al that included a sample of 5,978 individuals in six cities in Colombia, and related the effect of the SCIT in this parameter using an observational study from El-Qutob et al (28,29).…”

Section: Discussionmentioning

confidence: 99%

“…The resulting probabilities were converted to rates and re-expressed as 3-month probabilities for inclusion in the model. A 75.4% of reduction in the proportion of patients that reported unscheduled medical visits over a 9-month period reported by El-qutob et al was used in the model to reflect the effect of SCIT+ICS in the reduction in the probability of asthma exacerbations (29). This parameter was applied to the estimated baseline probabilities of an asthma exacerbation of 0.331 and 0.465 for AA and AA+AR patients, respectively (Table 1).…”

Section: Inputs and Data Sourcesmentioning

confidence: 99%

Cost-effectiveness of subcutaneous house dust mite allergen immunotherapy plus pharmacotherapy for allergic asthma

Padilla¹,

Zakzuk

Carrasquilla³

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Current cost-effectiveness evaluations of the house dust mite (HDM) allergen immunotherapy fail to account for its effect on the reduction of exacerbations and medications while considering potential differences across patient populations. We aimed to evaluate the cost-effectiveness of subcutaneous immunotherapy (SCIT) plus inhaled corticosteroids (ICS) vs ICS for pediatric and adult patients with allergic asthma (AA) and AA with Allergic rhinitis (AR) from the health care system perspective. Methods: A Markov model with a 3-month cycle length and a 10-year time horizon was developed. A hypothetical cohort of eight years old patients with controlled (or partially controlled) AA was the base case population. Health states were: treatment with GINA Step-3, Step-2, medication-free asthma, and all-cause death. Effectiveness was measured by the reduction in medication doses and exacerbations. Scenario analyses were conducted considering allergic AR as a comorbid condition and an

show abstract

“…The results regarding the evolution of unscheduled health care ( P <0.05) and rescue medication ( P <0.05) were published in the REME study ( Table 1 ). 12 …”

Section: Methodsmentioning

confidence: 99%

Savings associated with high-dose hypoallergenic house dust mite immunotherapy in rhinitis and/or asthma patients in Spain

Robaina¹,

Sánchez²,

Pérez³

2016

CEOR

View full text Add to dashboard Cite

ObjectivesTo quantify the cost difference between conventional symptomatic treatment of mite allergy and specific subcutaneous immunotherapy (SCIT).MethodsObservational, retrospective, and multicenter study was carried out in Spain in 2013. The medical records of 419 patients diagnosed with rhinitis and/or bronchial asthma for mite allergy were retrieved. Mean age was 24.9 years (standard deviation 14.4). The use of symptomatic medication (rescue and daily), diagnostic tests, unscheduled medical care, and sick leave days associated with SCIT treatment versus no-SCIT treatment was compared. Also measured was the SCIT treatment to no-SCIT treatment costs ratio: used resources (symptomatic medication, unscheduled medical care, diagnostic tests, and 3 years SCIT treatment and sick leave days) were quantified in euros. Efficacy (decreased resource usage) of first-year treatment was assumed during the remaining 2 years and also during the 3-year follow-up period.ResultsAfter a single year of SCIT, all quantified resources diminished significantly (P<0.05) from baseline. Estimated reduction in cost items included hospital resources (100% in hospitalizations, 82% in visits to the allergist, and 79% in emergency room visits), therapies (56% in rescue medication and 63% in daily medication), diagnostic tests (77%), and sick leave days (94%). Ratio of comparative calculation described as SCIT treatment versus non-SCIT treatment (or conventional symptomatic treatment) is 0.8.ConclusionDirect costs are reduced by 64% and indirect costs by 94%. SCIT of hypoallergenic preparation of dust mite (Acaroid®) allows cost savings versus conventional treatment. Estimated savings for the public National Health System are 5.7 times the cost of immunotherapy.

show abstract

Specific Immunotherapy for Rhinitis and Asthma with a Subcutaneous Hypoallergenic High-Dose House Dust Mite Extract: Results of a 9-Month Therapy

Abstract: Our results confirm in a real-world setting the findings from randomized clinical trials of high-dose house dust mites allergoid immunotherapy with a subcutaneous hypoallergenic high-dose house dust mite extract.

Cited by 7 publications

References 49 publications

Cost-effectiveness analysis of grass pollen specific immunotherapy in children with allergic rhinitis compared to the standard of care symptomatic treatment in Portugal

Cost-effectiveness analysis of grass pollen specific immunotherapy in children with allergic rhinitis compared to the standard of care symptomatic treatment in Portugal

Cost-effectiveness of subcutaneous house dust mite allergen immunotherapy plus pharmacotherapy for allergic asthma

Savings associated with high-dose hypoallergenic house dust mite immunotherapy in rhinitis and/or asthma patients in Spain

Contact Info

Product

Resources

About